A multicenter retrospective study comparing SRS followed by EGFR-TKI, WBRT followed by EGFR-TKI, and EGFR-TKI followed by SRS or WBRT has suggested that patients with NSCLC BMs with EGFR mutations who receive SRS followed by EGFR-TKI have the longest OS and are able to avoid the potential neurocognitive sequelae of WBRT49. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.